콘텐츠로 건너뛰기
Merck
모든 사진(3)

Key Documents

911593

Sigma-Aldrich

NanoFabTx microfluidic - nano

device kit for synthesis of 100-200 nm nanoparticles and liposomes

동의어(들):

Liposomes, Microfluidic kit, NanoFabTx device kit, Nanoformulation, Nanoparticle

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12162002
UNSPSC 코드:
41121811
NACRES:
NA.23

설명

Microfludic device kit for synthesizing nanparticles

Kit components :

  • Microfluidic chip x 1
  • Tubings and accessories

Quality Level

응용 분야

advanced drug delivery

일반 설명

NanoFabTx Microfluidic - nano device kit is a set of plug-and-play, easy-to-use microfluidic components that are compatible with Dolomite microfluidic systems and standard syringe pumps (not included). The device kit can be combined with our special nanoformulation kits (please visit www.sigmaaldrich.com/nanofabtx) to form nanoparticles or liposomes 100 to 200 nm in size. The device kit includes a comprehensive protocol, pre-assembled microfluidic chip manifold, tubing, and required accessories.

애플리케이션

NanoFabTx Microfluidic - nano device kit is designed to work with NanoFabTx - nano reagent kits (including 909637, 918075, and 907766) to synthesize drug-encapsulating liposome nanoparticles (LNP) and drug-encapsulating polymeric nanoparticles for targeted drug delivery research. Our device kit simplifies LNP formulation and polymeric nanoformulation by leveraging microfluidic technologies to achieve narrow size dispersity and high batch-to-batch consistency. The microfluidic chip manifold is chemically robust and compatible with a variety of solvents and therapeutics relevant in nanomedicine. The microfluidic chip geometries and controllable flow enable the user to achieve targetable particle diameters with homogenous shape and structure from 100 to 200 nm in size. By enabling users to easily fine-tune the synthetic parameters, our microfluidic-based tool allows scalable synthesis of drug-encapsulating nanocarriers for researchers in the field of precision medicine, drug discovery, and nanoparticle cancer treatment.

특징 및 장점

  • Step-by-step microfluidic-based protocols developed and tested by our formulation scientists
  • Optimization of drug encapsulation and loading efficiency in nanoparticles and liposomes
  • Selection of optimal nanoparticle and liposome size of any size between 100-200 nm
  • Small reaction volumes to reduce waste of expensive reagents and therapeutics

법적 정보

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Andrew Gdowski et al.
Journal of nanobiotechnology, 16(1), 12-12 (2018-02-13)
The process of optimization and fabrication of nanoparticle synthesis for preclinical studies can be challenging and time consuming. Traditional small scale laboratory synthesis techniques suffer from batch to batch variability. Additionally, the parameters used in the original formulation must be
Xuanyu Li et al.
Advanced drug delivery reviews, 128, 101-114 (2017-12-27)
Microfluidic chips allow the rapid production of a library of nanoparticles (NPs) with distinct properties by changing the precursors and the flow rates, significantly decreasing the time for screening optimal formulation as carriers for drug delivery compared to conventional methods.
Samar Damiati et al.
Genes, 9(2) (2018-02-22)
Microfluidic devices present unique advantages for the development of efficient drug carrier particles, cell-free protein synthesis systems, and rapid techniques for direct drug screening. Compared to bulk methods, by efficiently controlling the geometries of the fabricated chip and the flow

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.